Cereno Scientific announces milestone has been reached as part of preclinical CS014 program
Cereno Scientific (XSAT: CRNO B) today announced that the progress made in preclinical program CS014 has triggered an undisclosed milestone payment to Emeriti Bio from which CS014 was acquired in 2019. CS014 is currently undergoing a preclinical development program in collaboration with the University of Michigan. Based on this progress a new patent application has been filed.
“When we acquired the CS014 program from Emeriti Bio back in 2019 we thought it was a good complement to our CVD portfolio showing exciting innovative properties. As we have continued its development our belief in this program has only grown stronger”, says Sten R. Sörensen, CEO at Cereno Scientific. “It is pleasing to see the new data generated for CS014 forming the basis of a new patent application. We are looking forward to communicating more about this promising program later this year.”
The CS014 program was acquired from Emeriti Bio in March 2019 and has since been developed in a collaboration between Cereno and Emeriti Bio. A preclinical development program is now being conducted with CS014 in collaboration with the University of Michigan. The aim of the program is to successfully bring a drug candidate into a clinical Phase I program.
CS014 is a new histone deacetylase inhibitor (HDACi) program and is Cereno’s second HDACi program based on epigenetic modulation following the ongoing development of CS1. The program is being developed for the treatment of cardiovascular diseases.
Emeriti Bio is a combined biotech and contract research organisation (CRO) company that focuses on taking discoveries through patenting, pre-clinical and early clinical research in close collaboration with partners. The company was founded in 2015 by five former AstraZeneca researchers representing a wide knowledge of pharmaceutical research and development.
For further information, please contact:
Daniel Brodén, CFO
Phone: +46 768 66 77 87
Email: info@cerenoscientific.com
http://www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.